Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TK1 | P04183 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TK2 | O00142 | 2/20 | 0.33 |
| ▸ | PYGM | P11217 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079292 | 0.81 | LMNA (0.39) | LMNASMN1; SMN2ADRA1AALOX12BLM | |
| SCHEMBL5080168 | 0.81 | LMNA (0.56) | LMNASMN1; SMN2ADRA1AALOX12BLM | |
| SCHEMBL5080171 | 0.81 | LMNA (0.56) | LMNASMN1; SMN2ADRA1AALOX12BLM | |
| SCHEMBL7123550 | 0.81 | LMNA (0.39) | LMNASMN1; SMN2ADRA1AALOX12BLM | |
| SCHEMBL5076221 | 0.78 | ALB (0.39) | LMNASMN1; SMN2BLMALDH1A1ALB | |
| SCHEMBL7124525 | 0.75 | BLM (0.63) | LMNAADRA1ABLMALDH1A1ALB | |
| SCHEMBL7116002 | 0.73 | LMNA (0.43) | LMNASMN1; SMN2ADRA1AALOX12BLM | |
| SCHEMBL28334419 | 0.73 | PYGM (0.63) | TK2PYGM | |
| SCHEMBL7115997 | 0.73 | LMNA (0.43) | LMNASMN1; SMN2ADRA1AALOX12BLM | |
| SCHEMBL7125885 | 0.72 | TK1 (0.39) | LMNASMN1; SMN2ADRA1AALOX12BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293668-A1 | [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides | SCHINAZI RAYMOND F | 2008-11-27 | — | — | US | claimed |
| US-20040167140-A1 | [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides | EMORY UNIVERSITY | 2004-08-26 | — | — | US | claimed |
| EP-1361227-A2 | [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides | Emory University (US) | 2003-11-12 | — | — | EP | claimed |
| US-20020198173-A1 | [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides | EMORY UNIVERSITY | 2002-12-26 | — | — | US | claimed |
| US-20080293668-A1 | [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides | SCHINAZI RAYMOND F | 2008-11-27 | — | — | US | disclosed |
| US-7419966-B2 | [5-carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides | EMORY UNIVERSITY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040167140-A1 | [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides | EMORY UNIVERSITY | 2004-08-26 | — | — | US | disclosed |
| US-6680303-B2 | VIRICIDES FOR TREATING HIV AND HEPATITIS VIRUS | EMORY UNIVERSITY | 2004-01-20 | — | — | US | disclosed |
| EP-1361227-A2 | [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides | Emory University (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020198173-A1 | [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides | EMORY UNIVERSITY | 2002-12-26 | — | — | US | disclosed |
| US-6391859-B1 | HUMAN IMMUNODEFICIENCY VIRUS; VIRICIDES | EMORY UNIVERSITY | 2002-05-21 | — | — | US | disclosed |
| US-6232300-B1 | ADMINISTERING AS HEPATITIS B VIRICIDE | EMORY UNIVERSITY | 2001-05-15 | — | — | US | disclosed |
| US-5905070-A | HUMAN T-CELL LEUKEMIA/LYMPHOMA AND HEPATITIS B VIRICIDES; AIDS | EMORY UNIVERSITY (US) | 1999-05-18 | — | — | US | disclosed |
| US-5703058-A | TREATMENT OF HIV AND HEPATITIS B | EMORY UNIVERSITY (US) | 1997-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293668-A1 | [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides | DUT, NUDT1, PNP | LMNA 1598/4885SMN1; SMN2 1959/4885ADRA1A 3055/4885 |
| US-20020198173-A1 | [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides | DUT, NUDT1, PNP | LMNA 1735/4885SMN1; SMN2 1970/4885ADRA1A 3112/4885 |
| US-20040167140-A1 | [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides | DUT, NUDT1, PNP | LMNA 1735/4885SMN1; SMN2 1970/4885ADRA1A 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.